Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
03/2002
03/21/2002WO2002022677A2 Variants of allergenic proteins of the group 2 of dermatophagoides
03/21/2002WO2002022657A2 Peptide antagonist of multiple chemokine receptors and uses thereof
03/21/2002WO2002022630A1 Purine derivatives
03/21/2002WO2002022621A2 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS
03/21/2002WO2002022620A2 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f2$g(a) antagonists
03/21/2002WO2002022615A1 Alpha v integrin receptor antagonists
03/21/2002WO2002022611A2 Caspase inhibitors and uses thereof
03/21/2002WO2002022610A1 Isoxazoles and their use as inhibitors of erk
03/21/2002WO2002022608A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022607A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022606A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022605A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022604A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022603A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022602A2 Triazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022601A1 Pyrazole compounds useful as protein kinase inhibitors
03/21/2002WO2002022599A2 Chemokine receptor binding heterocyclic compounds
03/21/2002WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
03/21/2002WO2002022572A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
03/21/2002WO2002022562A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
03/21/2002WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
03/21/2002WO2002022559A2 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
03/21/2002WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
03/21/2002WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
03/21/2002WO2002022169A2 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
03/21/2002WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents
03/21/2002WO2002022161A2 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases
03/21/2002WO2002022160A2 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism
03/21/2002WO2002022153A2 Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
03/21/2002WO2002022151A2 Use of glp-1 and flp-2 peptides for treatment of bone disorders
03/21/2002WO2002022150A2 Medicament containing activated antithrombin iii
03/21/2002WO2002022135A1 Creatine ester pronutrient compounds and formulations
03/21/2002WO2002022134A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
03/21/2002WO2002022129A1 A method of analgesia
03/21/2002WO2002022128A1 A method of local anesthesia and analgesia
03/21/2002WO2002022124A1 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
03/21/2002WO2002022123A1 Alpha v integrin receptor antagonists
03/21/2002WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
03/21/2002WO2002022109A2 Patch comprising diclofenac
03/21/2002WO2002022108A1 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
03/21/2002WO2001087846A3 Tricyclic pyrazole derivatives as protein kinase inhibitors
03/21/2002WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta
03/21/2002WO2001078760A3 Method for treating pain by peripheral administration of a neurotoxin
03/21/2002WO2001078703A3 Methods and compositions for modulating alpha adrenergic receptor activity
03/21/2002WO2001078702A3 Methods and compositions for modulating alpha adrenergic receptor activity
03/21/2002WO2001077376A8 Diagnosis of diseases associated with metastasis
03/21/2002WO2001077164A8 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis
03/21/2002WO2001074379A3 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
03/21/2002WO2001072322A3 High dosage parenteral administration of lactoferrin
03/21/2002WO2001068859A3 Il-17 receptor like molecules and uses thereof
03/21/2002WO2001068568A3 Il-8 receptor antagonists
03/21/2002WO2001066099A3 Use of quinazoline derivatives as angiogenesis inhibitors
03/21/2002WO2001064165A3 Il-8 receptor antagonists
03/21/2002WO2001062942A3 MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS
03/21/2002WO2001062905A3 Integrin antagonists
03/21/2002WO2001060319A3 Polyhydroxylated benzene-containing compounds
03/21/2002WO2001058954A3 Trade molecules and uses related thereto
03/21/2002WO2001055106A3 Novel melanocortin receptor agonists and antagonists
03/21/2002WO2001051638A3 Drug metabolizing enzymes
03/21/2002WO2001051057A3 Glycosides and orthoester glycosides of glucocorticoids and uses thereof
03/21/2002WO2001042205A3 Treatment of inflammatory bowel disease with vitamin d compounds
03/21/2002WO2001034136A3 Use of adatanserin for the treatment of neurodegenerative conditions
03/21/2002WO2001030375A3 Use of gdnf for treating corneal defects
03/21/2002WO2001030334A3 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation
03/21/2002WO2001014372A3 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
03/21/2002US20020035386 Therapeutic light source and method
03/21/2002US20020035264 Therapy for vision disorders
03/21/2002US20020035262 7-hetero-bicyclo[2.2.1]-heptanes
03/21/2002US20020035243 Drug complexes
03/21/2002US20020035144 Solubility, bioavailability; antiinflammatory agents
03/21/2002US20020035140 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/21/2002US20020035127 Phenylalanine derivatives
03/21/2002US20020035104 Integrin receptor inhibitors
03/21/2002US20020035094 Substituted pyridine compounds and methods of use
03/21/2002US20020035092 Propanoic acid derivatives
03/21/2002US20020035077 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
03/21/2002US20020035065 Selective MMP inhibitors having reduced side-effects
03/21/2002US20020034803 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
03/21/2002US20020034764 Diarylsulfonylurea binding proteins
03/21/2002US20020034540 Solid non-effervescent compressed dosage form comprising an ibuprofen medicament and an alkali metal carbonate or bicarbonate carrier material and compressible filler component combined with disintegrating component
03/21/2002US20020034534 Receptor loading dosage form containing therapeutic agent and extended-release dosage form containing therapeutic agent administered concurrently
03/21/2002US20020034513 MHC complexes and uses thereof
03/21/2002US20020034393 Vector
03/21/2002US20020033174 Inhalable aerosol medicament for the treatment or prevention of pain
03/21/2002DE10045047A1 Arzneimittel enthaltend aktiviertes Antithrombin III Medicines containing activated antithrombin III
03/21/2002DE10044325A1 Neue MMP-2-Derivate als Inhibitoren des Integrins avbeta3 New MMP-2 derivatives as inhibitors of the integrin avbeta3
03/21/2002DE10026678C1 Transdermal patch for delivery of non-steroidal antiinflammatory agent, containing e.g. alkyl-pyrrolidone, metal salt, surfactant and polymers, provides good drug release and absorption properties
03/21/2002CA2432780A1 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f25g(a) antagonists
03/21/2002CA2422829A1 Patch comprising diclofenac
03/21/2002CA2422828A1 Novel tumor-associated marker
03/21/2002CA2422603A1 Vectors for molecule delivery to cd11b expressing cells
03/21/2002CA2422586A1 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
03/21/2002CA2422376A1 Isoxazoles and their use as inhibitors of erk
03/21/2002CA2422288A1 Novel mammalian receptor genes and uses
03/21/2002CA2422233A1 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2aantagonists
03/21/2002CA2422163A1 Isolated human kinase proteins, nucleic acid molecules and uses thereof
03/21/2002CA2422095A1 Tweak receptor agonists as anti-angiogenic agents
03/21/2002CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
03/21/2002CA2422064A1 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
03/21/2002CA2422060A1 Compositions comprising mixtures of human cytokines and methods of producing the same
1 ... 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 ... 1272